Meeting NewsVideo

VIDEO: Onset, frequency of toxicities vary between CTLA-4, PD-L1 agents

NEW YORK — In this video commentary from HemOnc Today New York, Young Kwang Chae, MD, MPH, MBA, discussed how clinicians can best manage side effects from immune checkpoint inhibitors.

CTLA-4 and PD-L1 inhibitors may produce different side effects, according to Chae, an assistant professor at Northwestern Medicine Developmental Therapeutics Institute.

Clinicians “should not be shy” about using steroids early in the presence of severe toxicities, Chae said. Steroids should be used long enough and tapered slowly.

“Let’s just be very careful, in terms of managing the side effects and identifying these patients early on with intense clinical monitoring visits,” Chae said.

Disclosure: Chae reports consultant roles for Biodesix, Foundation Medicine, Guardant Health, and Immuneoncia, as well as a research grant from Bristol-Myers Squibb and honoraria from AstraZeneca, Merck and Roche.

NEW YORK — In this video commentary from HemOnc Today New York, Young Kwang Chae, MD, MPH, MBA, discussed how clinicians can best manage side effects from immune checkpoint inhibitors.

CTLA-4 and PD-L1 inhibitors may produce different side effects, according to Chae, an assistant professor at Northwestern Medicine Developmental Therapeutics Institute.

Clinicians “should not be shy” about using steroids early in the presence of severe toxicities, Chae said. Steroids should be used long enough and tapered slowly.

“Let’s just be very careful, in terms of managing the side effects and identifying these patients early on with intense clinical monitoring visits,” Chae said.

Disclosure: Chae reports consultant roles for Biodesix, Foundation Medicine, Guardant Health, and Immuneoncia, as well as a research grant from Bristol-Myers Squibb and honoraria from AstraZeneca, Merck and Roche.

    See more from HemOnc Today New York